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Quantitative bone histology in children with chronic renal failure.
Quantitative bone histology (on undecalcified sections following double
tetracycline labeling), radiographs, and biochemistry were studied in 47
children, ages 1 to 17 years, with glomerular filtration rates (GFR)
below 80 mI/mini! .73m2. The earliest histologic change was an in-
creased osteoid surface accompanied by increased osteoblast and
tetracycline surfaces. However, significant bone disease (increased
osteoclastic surface, fibrosis, increased osteoid area, increased mineral-
ization lag time, and reduced tetracycline uptake at osteoid surfaces)
occurred only at GFR below 30 mi/mm/i .73m2. Radiographs and
alkaline phosphatase were normal in 25% of children with significant
bone disease; parathyroid hormone was increased in 48% of children
without bone disease. Thus, these noninvasive investigations were poor
predictors of disease presence. GFR was the most sensitive indicator
because bone disease occurred only at GFR below 30 ml/minil.73m2
and was present in all children with GFR below 20 ml/minil.73m2. It
was concluded that bone histology is required for early detection of
bone disease and is an essential tool in experimental studies of renal
osteodystrophy. However, because the level of GFR will indicate the
presence or absence of bone disease in most children, bone biopsy can
be avoided generally in clinical practice.
Histologie osseuse quantitative chez des enfants ayant une insuffisance
rénale chronique. L'histologie osseuse quantitative (sur des sections
non décalcifiées, après double marquage a Ia tetracycline), les radiogra-
phies, et les donnees biochimiques étaient dtudié en 47 enfants âgés de I
a 17 ans ayant une filtration glomerulaire (GFR) inferieure a 80
mI/mn/I ,73m2. Le changement histologique le plus précoce était une
augmentation de Ia surface ostéoIde, associée a une augmentation des
ostoblastes, et de la surface marquee par Ia tetracycline. Néanmoins,
me maladie osseuse significative (augmentation de la surface ostéoclas-
tique, fibrose, augmentation de Ia surface ostéoIde, augmentation du
temps de minéralisation, diminution du marquage par la tetracycline sur
les surfaces osteoIdes) n'était apparente que pour des GFR inférieures a
30 ml/mn/l,73 m2. Les radiographies et les phosphatases alcalines
étaient normales chez 25% des enfants ayant une maladie osseuse
significative. L'hormone parathyroIdienne était élevée chez 48% des
enfants sans anomalie osseuse. Ainsi ces examens non invasifs se sont
avérés de mauvais indicateurs de Ia presence d'une ostéopathie. La
GFR était l'indicateur le plus sensible, puisque Ia maladie osseue
survenait uniquement pour une GFR inférieure a 30 mI/mn/I ,73 m2 et
&ait présente chez tous les enfants ayant une GFR inférieure a 20 ml!
mn/I ,73 m2. Il etait conclu que l'histologie osseuse est nécessaire pour
Ia detection précoce de l'osteopathie, et est un outil essentiel pour les
&udes experimentales de l'osteodystrophie renale. Néanmoins, puis-
que Ic degré de GFR indique la presence ou I'absence d'ostéopathie
chez La plupart des enfants, Ia biopsie osseuse peut habituellement étre
évitCe en pratique clinique.
Renal osteodystrophy occurs commonly in advanced renal
failure in adults [1] and children [21. Though the mechanisms
are not defined fully, major etiological factors in renal osteodys-
trophy are an increase in parathyroid hormone production, due,
in part, to phosphate retention [3] and a decrease in the
production of vitamin D metabolites [4]. The effects of renal
osteodystrophy are most marked in the immature skeleton and
may result in slipped epiphyses and other skeletal deformities.
The level of glomerular filtration rate (GFR) at which bone
disease first occurs must be known to allow early institution of
therapy. A variety of treatment options, in particular the new
vitamin D metabolites, is becoming available. The use of such
agents should be accompanied by a knowledge of the type and
severity of bone disease so that appropriate conditions for the
use of each can be established.
This study was carried out in children to determine the degree
of functional impairment at which bone disease occurs, the
distribution of lesions seen, and the predictive value of noninva-
sive investigations for the presence, type, and severity of renal
bone disease.
Methods
Patients. Forty-seven children (33 boys, 14 girls) with chron-
ic renal failure and GFR below 80 ml/minll.73m2 were studied.
The ages ranged from 0.9 to 17.2 years (mean age: 9.4 years).
Thirty-six children had renal disease of congenital origin (ob-
structive uropathy, 10; reflux nephropathy, 11; juvenile neph-
ronophthisis, 6; dysplastic kidneys, 6; triad syndrome, 2; oligo-
meganephronia, 1) and 11 had acquired renal disease (gb-
merulonephritis, 8; interstitial nephritis, 2; hemolytic-uremic
syndrome, 1). GFR was below 20 mllmin/l .73m2 in 23 children
in the study. Thirteen children with congenital renal disease
presented with a GFR below 20 mi/min/! .73m2 and before the
study five had been on dialysis for 0.1 to LI years (mean, 0.4
years). Nine children, with acquired renal disease, had had
GFR below 20 ml/min/I.73m2 for 0.5 to 2.0 years (mean, 0.9
years), and six of these had been on dialysis for 0,1 to 1.9 years
(mean, 0.8 years). Seven children, all with GFR below 20
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ml/min/1.73m2, were nephrotic for 0.4 to 13.6 years (mean 5.0
years) before the study was made.
Four children received hemodialysis in the hospital for two 5-
hr sessions per week, and four children received it at home for
three 6-hr sessions per week. The dialysis fluid contained 1.5
mmoles/liter of calcium and was magnesium free. Peritoneal
dialysis was given to three children in three 12-hr sessions per
week using dialysis fluid containing 2 mmoles/liter of calcium
and 0.75 mmoles/liter of magnesium. Five children (two on
dialysis) had received vitamin D2 (20,000 to 50,000 lU/day) for
0.3 to 3.2 years (mean, 1.3 years) before this study. A phos-
phate binder (aluminium hydroxide) was prescribed when nec-
essary to maintain the plasma phosphate concentration between
1.3 and 1.9 mmoles/liter.
Single doses of tetracycline (20 mg/kg; maximum dose 1 g)
were administered orally 25 days and 4 days before bone
biopsy. The total dose of tetracycline used was less than
amounts previously reported to cause tooth deformities and
discoloration in babies [51.
Control data for bone histology came from discarded trans-
cortical iliac bone chips from nine children, aged 1 to 14 years
(mean, 6.1 years), who underwent surgery for congenital dislo-
cation of the hip (seven children) or idiopathic scoliosis (two
children). Tetracycline was administered in the same doses
given to the patients.
The protocol was approved by the Research Committees of
the hospitals involved in the study; informed consent was
obtained from the children's parents.
Bone histology. Under sedation and local anesthesia, hori-
zontal bone biopsy specimens were obtained from the right
posterior superior iliac spine using an 8-gauge (2.5 mm diameter
core) Jamshidi needle (Kormed Inc., St. Paul, Minnesota). The
biopsy specimens were processed and quantified using methods
already described [61. Biopsy specimens were fixed in formalin,
dehydrated in ethanol, and embedded in a methyl methacrylate-
glycol methacrylate medium. Three consecutive sections were
cut: a S-pS section for histochemical staining for acid phospha-
tase activity in osteoclast cytoplasm [71, a section mounted
unstained for viewing under ultraviolet light for tetracycline
fluorescence, and a 5- section for pyronin staining for RNA in
osteoblasts. Aqueous toluidine blue was used for counter-stain.
A further three consecutive sections were taken 200 p. further
into the block so that the total section area of quantified
trabecular bone was 25 to 30 mm2. Following tracing on paper
using a camera lucida microscope attachment, quantitative data
were obtained using a Hewlett Packard 9864A digitizer inter-
faced to a Hewlett Packard 98l5A desk top computer (Hewlett
Packard, Loveland, Colorado). Woven bone was observed
under polarized light.
The following parameters were measured and calculated:
areas, total bone area, including osteoid, (% section area),
woven bone area (% trabecular bone area), and fibrosis area (%
section area); osteoid parameters, osteoid area (% trabecular
bone area), osteoid surface (% trabecular bone surface), indi-
rect osteoid width (obtained by dividing absolute osteoid area
by absolute osteoid surface), and direct osteoid width (mea-
sured at 100-p. intervals at osteoid seams with osteoblasts and
double tetracycline markers); formation parameters, the per-
centage of trabecular bone surface in contact with osteoblasts
(osteoblast surface % trabecular surface), the percentage of
trabecular bone surface taking up the second tetracycline label
(tetracycline surface % trabecular surface), the calcification
rate (p/day), and the bone formation rate (pJmm2/day). The
calcification rate measures the width of bone mineralized daily
and was obtained by dividing the mean distance between
tetracycline labels (measured at 100-p. intervals at osteoid
seams lined by osteoblasts) by the interval between administra-
tion of labels. This value was uncorrected for the obliquity of
the plane section. The bone formation rate was obtained by
multiplying the mean calcification rate (measured at all double
labels) by the absolute tetracycline labeled surface (single and
double markers) and dividing by the section area. A single label
may represent fusing of labels at a slowly forming surface or
alternatively initiation of a formative phase after administration
of the first label or termination of a formative phase before
administration of the second label. Single labels which could be
identified positively as first markers were excluded in the
measurement of tetracycline surface. Though some formation
occurs at single-labeled sites, inclusion of single and double
labels may lead to an over-estimation of tetracycline surface
and bone formation rate, while inclusion of double labels only
may underestimate these parameters.
Also measured were mineralization parameters using the
percentage of osteoid surface in contact with osteoblasts (osteo-
blast surface % osteoid surface), the percentage of osteoid
surface taking up the second tetracycline label (tetracycline
surface % osteoid surface), and the mineralization lag time
(days). The mineralization lag time [1] was used to measure the
delay between osteoid deposition and its mineralization and
was obtained by dividing the direct osteoid width by the
calcification rate. Resorption parameters were calculated using
the percentage of total trabecular bone surface in contact with
osteoclasts (osteoclast surface % trabecular surface) and the
osteoclast numbers (per mm2 section area).
Biopsies were classified as normal or as showing hyperpar-
athyroid bone disease, osteomalacia, or combined disease.
Hyperparathyroid bone disease was diagnosed when the osteo-
clast surface (% trabecular surface) exceeded 2.2% (2 SD above
control mean). Osteomalacia was diagnosed when the mineral-
ization lag time exceeded 22 days (2 SD above control mean) or
the percentage of osteoid surface with a tetracycline label (a
measure of the calcification front [8]) fell below 50% (2 SD
below control mean). Because osteoid accumulation may occur
in hyperparathyroid bone disease [1, 8], osteoid parameters
were not used to separate lesion types. In hyperparathyroid
bone disease, the rate of bone mineralization parallels the rate
of osteoid synthesis. Thus, an increase in mineralization lag
time indicated a delay in the onset of mineralization [1]. Bordier
and Tun Chot [8] showed that a reduction in mineralization
front (measured by tetracycline uptake or toluidine blue stain-
ing) in the presence of excess osteoid indicated defective
mineralization. Therefore, both parameters indicate abnormal
mineralization. In some patients tetracycline uptake may be
minimal and lag time unmeasurable while in others, with
associated hyperparathyroid bone disease, lag times may be
normal but the tetracycline uptake at osteoid seams is reduced.
In some patients, tetracycline uptake may be normal despite a
delay in the onset of mineralization as indicated by increased
mineralization lag times. Therefore, both parameters were
utilized to diagnose osteomalacia in this study.
Bone histology in children with renal failure 835
Table 1. Bone histology at various levels of glomerular filtration rate
Glomerular filtration, ml!min!1.73 m2
50 to 80 30 to 49 20 to 29 5 to 19 Dialysis Controls
Histological parametersc (N = 8) (N = 8) (N = 8) (N = 12) (N = 11) (N = 9)
Areas
Bone area, % section area 19 7 21 4 20 4 31 lOb 30 lOb 19 5
Woven bone area, % bone area 5 4 2 2 5 5 22 l8b 22 22b I 2
Fibrosis area, % section area 0 0 1 2 8 10 10 12 0
Osteoid parameters
Osteoid area, % bone area 9 4 7 3 13 5h 21 8b 26 12b 6 4
Osteoid surface, % trabecular surface 35 9 31 10 44 lOb 56 lOb 62 l5b 19 12
Indirect osteoid width, 14 4 14 1 16 3 23 6b 25 7b 14 4
Direct osteoid width, 18 2 17 2 20 3" 27 7" 30 12bd 14 3
Formation parameters
Osteoblast surface, % trabecular surface 26 6 24 9 33 6" 34 9b 31 16b 14 10
Tetracycline surface, % trabecular surface 26 7" 23 7 30 4" 30 8" 20 11 IS 8
Calcificationrate, JJday 1.1 0.2 1.1 0.2 1.1 0.1 1.2 0.3 1.1 0.3d 1.2 0.2
Bone formation rate, pJmm2lday 1018 469 848 404 1089 417 1610 750 1263 1526d 648 363
Mineralization parameters
Osteoblast surface, % osteoid surface 75 9 76 8 78 11 63 20 52 26 76 11
Tetracycline surface, % osteoid surface 74 10 73 8 70 11 55 16 35 23b 80 15
Mineralization lag time, days 17 2 16 2 19 2" 25 8" 29 16bd 14 4
Resorption parameters
Osteoclast surface, % trabecular surface
Osteoclast numbers, per mm2 section area
1.4 0.3
2.4 0.9
1.4 0.6
2.4 1.3
2.1 1.0
3.5 2.1
3.9
9.0
1.3"
5.6b
3.8
8.4
1.6"
5.0"
1.0 0.6
2.1 1.3
Values are given as mean 1 SD.
b Indicates significant difference from control values.
See text for explanation of parameters.
d Excludes one patient, in whom double tetracycline labels could not be distinguished.
Radiology. Radiographs of hands, wrists, knees, ankles, and
pelvis were examined for subperiosteal erosions, metaphyseal
changes, and Looser's zones by one radiologist who had no
knowledge of the bone histology. Fine grain, single emulsion
film was used for hand radiographs. No attempt was made to
analyze bone density or trabecular pattern.
Biochemistry. Fasting values for plasma calcium, inorganic
phosphorus, bicarbonate, creatinine, alkaline phosphatase,
parathyroid hormone (PTH), and 25-hydroxyvitamin D (25
OHD) were obtained on the day of biopsy or, in dialysis
patients, predialysis on the day before biopsy. Calcium was
measured by atomic absorption spectrophotometry and inor-
ganic phosphorus by the method of Fiske and Subbarow [9].
Bicarbonate, creatinine, and alkaline phosphatase were mea-
sured on a Technicon autoanalyser (Technicon Instruments
Corp., Ardsley, New York) using standard methods. PTH was
measured by a radioimmunoassay [10], which detects intact
hormone and carboxyl-terminal fragments. 25-OH vitamin D
was measured by a competitive protein binding assay [11].
Glomerular filtration rate was obtained from creatinine clear-
ance (Ccr) estimated from the formula:
Ccr(ml/minhl.73m2) = [48.6 x height (cm)]
[Plasma creatinine (pi.mole s/liter)].
This formula was adapted for use with SI units from that
derived by Schwartz et al [121. Heights were measured on the
day of biopsy. The calculated GFR correlated closely (r =0.96,
P < 0.01) with the GFR measured by the plasma clearance of
Technetium-99m DTPA complex in 20 children (unpublished
results).
Statistical evaluation. Group differences were determined by
analysis of variance, using transformation of data where neces-
sary to obtain homogeneity of variance. Because 21 parameters
were analyzed, only F values exceeding the critical value based
on a significance level of 0.002 (0.05 ÷ 21) were regarded as
significant. For parameters with significant F values, the signifi-
cance of differences between group means was determined by a
Bonferroni t test [13]. Because 15 possible comparisons existed
among group means for each parameter, only t values exceed-
ing the critical value based on a significance level of 0.003 (0.05
15) were considered to be significant. Relationships between
separate parameters were tested by correlation coefficients
using transformations to obtain normality of data. To avoid
incorrect assessment of significance where multiple tests of
correlation were performed, only values for r exceeding 0.49
were regarded as significant.
Results
Bone histology (Table 1). The earliest histologic change was
an increase in mean osteoid surface (Fig. 1), though individual
values exceeding 2 SD of control mean were seen in only two
children with GFR 30 to 80 mI/min/! ,73m2. Increased osteoid
surface was associated with increased osteoblast and tetracy-
cline surfaces, in undialysed patients (Table 1). However, at
GFR below 20 ml/min/l.73m2 absolute changes in osteoid
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Table 2. Correlations between biochemical and histological parameters in undialyzed patients (N = 36)
20
•10
20 10 Dialysis
Fig. 1. Osteoid surface % bone surface (. •) and tetracycline
surface % osteoid surface (s___.) compared to GFR. Values for
each group are plotted at the mean GFR for each group and represent
mean 1 SD. Data points significantly different from control are
indicated in Table 1.
surface exceeded those in tetracycline surface so that tetracy-
cline surface % osteoid surface fell (Fig. 1). Although correla-
tions (Table 2) demonstrate the worsening of many histological
parameters with decreasing GFR, mean values for parameters,
other than osteoid and tetracycline surfaces, differing from
control means, and individual values exceeding 2 SD of control
mean only occurred at GFR below 30 ml/min/l .73m2 (Table 1).
Thus significant bone disease occurred only at GFR below 30
ml/min/l.73m2 and was present in all children with GFR below
20 ml/min/1 .73m2 (Fig. 2). Of 26 children with bone disease, 15
had osteomalacia or mixed disease. Seven children satisfied
both criteria for the diagnosis of osteomalacia while four had
reduced tetracycline surface (% osteoid surface) only, and four
had elevated mineralization lag times only. Though osteoid
parameters were not used to separate lesion types, patients with
osteomalacia or combined disease had significantly higher (P <
60 40 20 Dialysis
GFR, rn//mm/i .73m2
Fig. 2. Presence and distribution of bone lesions at various GFRs.
0.001) osteoid areas (27 9%), osteoid surfaces (65 9%), and
indirect osteoid widths (26 6%) than patients with hyperpara-
thyroid bone disease alone (osteoid area, 15 4%; osteoid
surface, 47 8%; osteoid width, 19 5%). Mean calcification
rates (Table 1) did not differ between groups. However, in
children with osteomalacia alone (one child) or predominant
osteomalacia (osteoclastic surface below 3%; four children), the
mean calcification rate (0.9 0.1 1i/day) was significantly lower
than control values (1.2 0.2 pJday; P < 0.001). Contrary to
the findings in adult patients with chronic renal failure, double
labels could be separated in 14 of 15 children with osteomalacia.
Persistence of coupling in undialyzed patients between bone
resorption and formation despite defective mineralization is
demonstrated by correlations (Table 3).
Dialysis patients (Table 1) differed from undialyzed children
with a GFR ranging from 5 to 19 ml/min/l.73m2 only in having
reduced tetracycline surface (% total surface and % osteoid
surface). In general bone disease was not more severe in
children with congenital renal disease when compared to chil-
dren with acquired renal disease (Figs. 3 and 4). However, the
four children with the most extensive radiological changes had
congenital renal disease and more severe histological disease
(osteoid area, 35 2%; osteoclast numbers, 16.4 5.8 per
mm2; fibrosis area, 35 24%). No significant differences in
mean values for histological parameters were found between
children on vitamin D therapy and other children with bone
disease, so treated children were not considered as a separate
Histological parameters
GFR PTH
ml/min/1.73 m2 ng/ml
r P r P
Alkaline Inorganic
phosphatase Calcium phosphorus
U/liter mmoles/liter mmoles/liter
r P r P r P
Bone area, % section area —0.52 <0.01 NS 0.51 <0.01 —0.51 <0.01 NS
Fibrosis area, % bone area —0.72 <0.001 0.67 <0.001 0.57 <0.001 —0.58 <0.001 0.50 <0.01
Osteoid area, % bone area —0.66 <0.001 0.64 <0.001 0.52 <0.01 NS NS
Osteoid surface, % bone surface —0.64 <0.001 0.69 <0.001 0.54 <0.001 —0.50 <0.01 NS
Direct osteoid width, i.
Bone formation rate, iimm2/day
—0.63 <0.001
NS
0.69 <0.001
NS
0.52
0.55
<0.01
<0.001
—0.66 <0.001
NS
0.59 <0.001
NS
Tetracycline surface, % osteoid surface 0.51 <0.01 NS NS 0.52 <0.01 NS
Mineralization lag time, days —0.59 <0.001 NS NS —0.59 <0.001 NS
Osteoclastic surface, % bone surface —0.67 <0.001 0.66 <0.001 NS NS 0.51 <0.01
Osteoclast numbers, per mm2 section area —0.65 <0.001 0.66 <0.001 0.56 <0.001 NS NS
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Table 3. Correlations between resorption and osteoid and formation
parameters in undialyzed patients (N 36)
Osteoclast
Osteoclastic numbers, per
surface, % mm2 section
bone surface area
Histological parameters r P r P
Bone area, % section area 0.53 <0.001 0.66 <0.001
Woven bone area, % bone area 0.55 <0.001 0.68 <0.001
Fibrosis area, % section area 0.77 <0.001 0.86 <0.001
Osteoid area, % bone area 0.71 <0.001 0.66 <0.001
Osteoid surface, % bone surface 0.71 <0.001 0.67 <0.001
Osteoblast surface, % bone surface 0.56 <0.001 NS
Tetracycline surface, % bone surface 0.57 <0.001 NS
Calcification rate, pJday NS NS
Bone formation rate, pJmm2/day 0.73 <0.001 0.78 <0.001
group. Also no significant differences in mean values for
histological parameters were found between nephrotic children
and other children with bone disease.
Radiology. Radiological changes were present in ten children
at the time of study. In addition subperiosteal erosions and
metaphyseal changes had healed in three children on vitamin D
therapy. Erosions and metaphyseal changes occurred together
in four children, with congenital renal disease, and more severe
histological disease. Radiological changes were not present in
five of six children in whom osteomalacia was the sole or
predominant lesion.
Biochemistry (Table 4). Alkaline phosphatase was elevated in
four children without and in 14 children with bone disease. PTH
was elevated in ten children without and in 23 children with
bone disease. 25-OH vitamin D levels were reduced in children
with a GFR below 20 ml/min/1.73m2; however, when seven
nephrotic children (mean 25-OH vitamin D, 23 ng/ml; range, 15
to 51 nglml) were excluded, values were similar in all groups.
The mean 25-OH vitamin D in vitamin D-treated children was
211 ng/ml (range, 107 to 364 ng/ml). In nonvitamin D-treated
children, 25-OH vitamin D levels did not correlate with any
histological parameters. Calcium concentrations correlated in-
versely with osteoid and mineralization parameters only when
dialysis patients were excluded (Table 2). When dialysis pa-
tients were included PTH and alkaline phosphatase continued
to correlate with resorption and osteoid parameters.
Discussion
Renal bone disease as defined by increased bone resorption
(osteoclastic surface) with or without defective bone mineral-
ization (mineralization lag time, tetracycline uptake at osteoid
surface) only became apparent in children in this study at a
GFR below 30 ml/min/l.73m2. However, at a higher GFR bone-
forming surfaces were increased. Increase in osteoid surface
cannot be attributed to defective mineralization because it was
accompanied by increases in osteoblast and tetracycline sur-
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Table 4. Biochemical parameters at various levels of glomerular filtration rate
Glomerular filtration rate, mlImin/1.73 m2
50 to 80 30 to 49 20 to 29 5 to 19 Dialysis
Biochemical parameters (N = 8) (N = 8) (N = 8) (N = 12) (N = 11) Normal values
Calcium, mmoles/liter 2.39 0.l2 2.34 0.14 2.36 0.16 2.17 0.20 2.30 0.23 2.50 0.13
Inorganic phosphorus, mmoles/liter 1.43 0.21 1.54 0.31 1.52 0.16 1.92 0.35 1.65 0.31 1.60 0.15
Venous bicarbonate, mmoleslliter 23 2 20 3 20 4 20 4 25 4 22 I
Alkaline phosphatase, U/liter 236 70 248 67 225 66 406 241 330 334 150 75
Parathyroid hormone, ng/ml 0.52 0.54 0.52 0.37 1.14 0.96 2.52 1.20 1.71 1.20 0.30 0.15
25-hydroxy vitamin D, nglml 59 21 54 35 54 16 41 27b 42 310 38 13"
a Values are given as mean 1 SD.
b Excludes three children taking vitamin D2.
Excludes two children taking vitamin D2.
d Adult normal values quoted.
face. Parathyroid hormone stimulates osteoblastic and osteo-
clastic activity, so increased forming surfaces could represent
early hyperparathyroid bone disease. Malluche et al [14] noted
increased osteoid surface and woven osteoid at a GFR exceed-
ing 50 mI/mm/i .73m2 and attributed these to parathyroid over-
activity. However, children with a GFR ranging between 30 to
80 mI/mm/I .73m2 and elevated PTH levels did not have higher
values for bone forming surfaces than children with normal
PTH levels. It can be argued that control data obtained from
children with scoliosis and congenital dislocation of the hip may
not be ideal because both diseases and the immobilization
associated with their treatment may result in alterations in bone
dynamics. However, control data on normal French and Ameri-
can children have been reported previously [15] for a limited
number of histological parameters and these results are similar
to the control data reported in this study.
There is little published information on bone histology in
children with varying degrees of renal impairment. Norman et
al [16] using similar diagnostic criteria, found significant bone
disease in children with a GFR below 50 ml/min!1.73m2. The
reasons for the difference are not obvious. Their paper did not
provide quantitative data on patients and controls so adequate
comparison of the two studies is not possible. The difference
may be methodological because techniques in this study utilize
specific stains for osteoclast [7] and osteoblast [6] identification
and utilize tetracycline uptake [17] to identify mineralization
rather than toluidine blue staining [8]. Low levels of 25-OH
vitamin D have been described in association with osteomalacia
in some adults with end-stage renal failure [18, 19] and in adults
with nephrotic syndrome and normal renal function [20]. How-
ever, mean values for 25-OH vitamin D were not different in the
present study from values reported by Norman et at [16].
Evidence of increased bone resorption and defective mineral-
ization also has been found in adults [14] at a GFR below 50
ml/min/i.73m2; 25-OH vitamin D values were not reported.
The most reliable predictor of the presence of bone disease
was the glomerular filtration rate. All children, regardless of
age, type, and duration of renal disease, with a GFR below 20
ml/min/1.73m2 had histological bone disease. However, exten-
sive radiological changes indicating severe hyperparathyroid
bone disease [21] occurred only in children with presumed long-
standing renal impairment of congenital origin, who presented
in advanced renal failure. Thus, a low GFR per se determines
the presence of renal osteodystrophy while the duration of a
low GFR determines its severity. It has been stated [22] that
skeletal deformities occur in very young children before renal
function is seriously impaired, that is, at serum creatinine
concentrations below 3 mg/dl. However, in small children
creatinine concentrations of 2 to 3 mg/dl indicate a GFR below
20/mt/mm/i .73m2, a level of renal functional impairment at
which renal osteodystrophy would be expected to occur.
Radiological changes and increased alkaline phosphatase
values were not seen in 25% of children with histological
disease, a proportion similar to that described by Norman et al
[16]. As found previously [23], radiographic changes were more
predictive of hyperparathyroid bone disease than osteomalacia.
Unlike previous studies [16, 24], PTH did not prove an ade-
quate indicator of bone disease because elevated levels oc-
curred in 48% of children without significant bone disease.
Thus, the data emphasize the value of bone histology in the
detection of bone disease and of osteomalacia in particular.
It is generally agreed, since the studies of Dent, Harper, and
Philpot [25], that renal osteodystrophy in children requires
vitamin D therapy. However, vitamin D administration may
result in hypercalcemia and metastatic calcification. There is
some evidence [26], although disputed [27], that vitamin D
therapy accelerates renal functional deterioration. Thus, vita-
min D administration should be restricted to children known to
have bone disease. Some studies [28, 29], but not all [30],
suggest that 25-OH vitamin D and 24,25-dihydroxyvitamin D
may be more effective therapies for osteomalacia than is 1,25-
dihydroxyvitamin D. Thus, a knowledge of the predominant
lesion present may be necessary to obtain maximum benefit
from therapy. Noninvasive investigations are unreliable for
diagnosis, particularly when osteomalacia predominates [23].
Consequently, for early detection and accurate delineation of
the type of bone disease, bone histology is necessary. Although
a bone biopsy is a safe and simple procedure, it is nevertheless
an invasive procedure, requiring a day in the hospital for the
child, and is associated with the risks relative to heavy seda-
tion. Data from the present study provide a basis on which
recommendations for bone biopsy in individual children can be
made. Children in Australia with a GFR above 30 mu
min/1.73m2 do not have significant bone disease. Because 25-
OH vitamin D levels in Australian children are similar to those
in American children, this data may also be applicable to
American children. Most children with a GFR below 30
ml/min/1.73m2 have bone disease and may require vitamin D
Bone histology in children with renal failure 839
therapy. Thus, children with a GFR below 30 ml/min/1.73m2
without radiological changes or elevated alkaline phosphatase
levels require bone biopsies to determine the presence and
severity of disease and the need for vitamin D therapy. Bone
histology is an essential tool in studies of renal osteodystrophy
and the efficacy of therapy with vitamin D metabolites.
Acknowledgments
The results of this study were presented in part at the 14th European
Symposium on Calcified Tissues, Rhodes (April ito 5, 1979), and at the
Fifth International Pediatric Nephrology Symposium, Philadelphia,
Pennsylvania (October 6 to 10, 1980). Dr. R. A. Evans received grants
from the Department of Veterans' Affairs and the National Health and
Medical Research Council. Parathyroid hormone and 25-hydroxyvita-
mm D assays were performed in the laboratory of Professor S. Posen
(Sydney Hospital, Sydney, Australia). We acknowledge the help of
Drs. L. P. Roy, A. R. Rosenberg, J. S. Horvath, D. J. Tiller, J. F.
Mahoney, and J. H. Stewart, who provided patients for the study and
the help of Dr. K. Kozlowski, who interpreted the radiographs.
Reprint requests to Dr. E. M. Hodson, Department of Nephrology,
Royal Alexandra Hospital for Children, P.O. Box 34, Camperdown.
N.S.W. 2050, Australia
References
1. SHERRARD DJ, BAYLINK Di, WERGEDAL JE, MALONEY NA:
Quantitative histological studies on the pathogenesis of uremic
bone disease. J Clin Endocrinol Metab 39:119—135, 1974
2. MEHLS 0, KREMPIEN B, RITZ E, SCHARER K, SCHULER HW:
Renal osteodystrophy in children on maintenance haemodialysis.
Proc Eur Dial Transplant Assoc 10:197—201, 1973
3. SLATOPOLSKY E, RUTHERFORD E, HRUSKA K, MARTIN K, KLAHR
S: How important is phosphate in the pathogenesis of renal
osteodystrophy? Arch Intern Med 138:848—852, 1978
4. MASSRY SO, RITZ E: The pathogenesis of secondary hyperpara-
thyroidism in renal failure. Is there a controversy? Arch Intern Med
138:853—856, 1978
5. WALLMAN IS, HILTON HB: Teeth pigmented by tetracycline.
Lancet 1:827—829, 1962
6. DUNSTAN CR, EVANS RA: Quantitative bone histology: A new
method. Pathology 12:255—264, 1980
7. EVANS RA, DUNSTAN CR, BAYLINK Di: Histochemical identifica-
tion of osteoclasts in undecalcified sections of human bone. Miner
Electrolyte Metabol 2:179—185, 1979
8. BORDIER P, TUN CHOT 5: Quantitative bone histology in metabolic
bone disease. C/in Endocrinol Metab 1:197—215, 1972
9. FISKE CH, SUBBAROW Y: The colorimetric determination of phos-
phorus. J Biol Chem 66:375—400, 1925
10. KLEEREKOPER M, INGHAM JP, MCCARTHY SW, POSEN 5: Parathy-
roid hormone assay in primary hyperparathyroidism: Experience
based on a radioimmunoassay based on commercially available
reagents. Clin Chem 20:369—375, 1974
11. MASON RS, POSEN 5: Some problems associated with assay of 25-
hydroxycalciferol in human serum. Clin Chem 23:806—810, 1977
12. SCHWARTZ Gi, HAYCOCK GB, EDELMANN CM iR, SPITZER A: A
simple estimate of glomerular filtration rate in children derived
from body length and plasma creatinine. Pediatrics 58:259—263,
1976
13. MILLER RG: Simultaneous statistical inference. New York,
McGraw Hill. 1966, p. 67
14. MALLUCHE HH, RITZ E, LANGE PH, KUTSCHERA J, HODGSON M,
SEIFFERT U, SCHOEPPE W: Bone histology in incipient and ad-
vanced renal failure. Kidney mt 9:355—362. 1976
15. WITMER 0, MARGOLIS A, FONTAINE 0, FRITSCH J, LENOIR 0,
BROYER M, BALSAN 5: Effects of 25-hydroxycholecalciferol on
bone lesions of children with terminal renal failure. Kidney mt
10:395—408, 1976
16. NORMAN ME, MAZUR AT, BORDEN S IV, GRUSKIN A, ANA5T C,
BARON B, RASMUSSEN H: Early diagnosis of juvenile renal osteo-
dystrophy. J Pediatr 97:226—232, 1980
17. FROST HM: Tetracycline-based histological analysis of bone re-
modelling. Calcif Tissue mt 3:211—237, 1969
18. EAsTwooD JB, HARRIS E, STAMP TCB, DE WARDENER HE:
Vitamin-D deficiency in the osteomalacia of chronic renal failure.
Lancet 2:1322—1326, 1976
19. MASON RS, LISSNER D, WILKINSON M, P05EN S: Vitamin D
metabolites and their relationship to azotaemic osteodystrophy.
Clin Endocrinol 13:375—385, 1980
20. MALLUCHE HH, GOLDSTEIN DA, MASSRY SG: Osteomalacia and
hyperparathyroid bone disease in patients with nephrotic syn-
drome. J C/in Invest 63:494—500. 1979
21. KREMPIEN B, MEHLS 0, RITZ E: Morphological studies on patho-
genesis of epiphyseal slipping in uremic children. Virchows Arch
[Pathol Anat] 362:129—134, 1974
22. H5U AC, KooH SW, CUMMING WA, ARBUS GS, FORNASIER VL,
FRASER D: Renal osteodystrophy in childhood—an unexpectedly
common complication of chronic renal failure. Annals of Royal
College of Physicians and Surgeons of Canada 12:87, 1979
23. HRUSKA KA, TEITELBAUM SL, KOPELMAN R, RICHARDSON CA,
MILLER P, DEBMAN i, MARTIN K, SLATOPOLSKY E: The predict-
ability of the histological features of uremic bone disease by non-
invasive techniques. Metab Bone Dis Rel Res 1:39—44, 1978
24. POSTLETHWAITE Ri, HILL LF, HOUSTON IB: Detection and man-
agement of renal osteodystrophy in children. Arch Dis Child
51:236, 1976
25. DENT CE, HARPER CM, PHILPOT GR: The treatment of renal
glomerular osteodystrophy. QJMed 30:1—31, 1961
26. CHRISTIANSEN C, R$DRRO P, CHRISTENSEN MS, HARTNACK B,
TRANSB$L 1: Deterioration of renal function during treatment of
chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet
2:700—703, 1978
27. MASSRY SG, GOLDSTEIN DA: Is calcitriol (1.25(OH),D3) harmful to
renal function? JAMA 242:1875—1876, 1979
28. FOURNIER A, BORDIER P, GUERI5 J. SEBERT JL, MARIE P.
FERRIERE C, BEDROSSIAN J, DELUCA HF: Comparison of Ia-
hydroxycholecalciferol and 25-hydroxycholecalciferol in the treat-
ment of renal osteodystrophy: Greater effect of 25-hydroxychole-
calciferol on bone mineralization. Kidney tnt 15:196—204, 1979
29. BORDIER P, RASMUSSEN H, MARIE P, MIRAVET L, GUERIS J,
RYCKWAERT A: Vitamin D metabolites and bone mineralization in
man. J Clin Endocrinol Metab 46:284—294, 1978
30. MALLUCHE HH, GOLDSTEIN DA, MASSRY SO: Management of
renal osteodystrophy with l,25(OH)2D3. II. Effects on histopathol-
ogy of bone: Evidence for healing of osteomalacia. Miner Electro-
lyte Metabol 2:48—55, 1979
